Allogeneic umbilical cord blood red cell concentrates: An innovative blood product for transfusion therapy of preterm infants

Maria Bianchi, Carmen Giannantonio, Serena Spartano, Maria Fioretti, Alessandra Landini, Anna Molisso, Ghennet Mikael Tesfagabir, Assunta Tornesello, Ombretta Barbagallo, Caterina Giovanna Valentini, Giovanni Vento, Gina Zini Tanzi, Costantino Romagnoli, Patrizia Papacci, Luciana Teofili

Risultato della ricerca: Contributo in rivistaArticolo in rivista

18 Citazioni (Scopus)


Background: Preterm infants often receive blood transfusions early in life. In this setting, umbilical cord blood (UCB) might be safer than adult blood (A) with respect to infectious and immunologic threats. Objectives: To evaluate, as a first objective, the feasibility of fulfilling transfusion needs of preterm infants with allogeneic UCB red blood cell (RBC) concentrates and, as a secondary objective, to assess the safety of allogeneic cord blood transfusions. Methods: At the Neonatal Intensive Care Unit and the UNICATT Cord Blood Bank of 'A. Gemelli' Hospital in Rome, a prospective study was carried out over a 1-year period, enrolling newborns with gestational age ≤30 weeks and/or birth weight ≤1,500 g requiring RBC transfusions within the first 28 days of life. At first transfusion, patients were assigned to receive UCB-RBCs or A-RBCs depending on the availability of ABO-Rh(D)-matched UCB-RBC units. The same regimen (UCB-RBC or A-RBC units) was thereafter maintained, unless ABO-Rh(D)-matched UCB-RBC units were not available. Results: Overall, 23 UCB-RBC units were transfused to 9 patients; the requests for UCB-RBC units were met in 45% of patients at the first transfusion and in 78% at the subsequent transfusions. At a median follow-up of 57 days (range 6-219), no acute or delayed transfusion-related adverse events occurred. Hematocrit gain after transfusion and time intervals between transfusions were similar in the UCB-RBC and A-RBC group, as well. Conclusions: Transfusing allogeneic UCB-RBC units in preterm infants appears a feasible and safe approach, although the transfusion needs of our study population were not completely covered. More data are necessary to validate this novel transfusion practice.
Lingua originaleEnglish
pagine (da-a)81-86
Numero di pagine6
Stato di pubblicazionePubblicato - 2015


  • Adult red blood cells
  • Availability of umbilical cord blood
  • Birth Weight
  • Developmental Biology
  • Erythrocyte Transfusion
  • Feasibility Studies
  • Female
  • Fetal Blood
  • Follow-Up Studies
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Intensive Care Units, Neonatal
  • Male
  • Pediatrics, Perinatology and Child Health
  • Preterm infants
  • Prospective Studies
  • Safety of umbilical cord blood
  • Umbilical cord blood transfusion


Entra nei temi di ricerca di 'Allogeneic umbilical cord blood red cell concentrates: An innovative blood product for transfusion therapy of preterm infants'. Insieme formano una fingerprint unica.

Cita questo